MANILA PILLAI: Open Payments
NPI 1942739784 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$401 in 18 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $162 · 2025 $401
Food & beverage: $401
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $206 |
| Daiichi Sankyo Inc. | 2 | $58 |
| Eisai Inc. | 1 | $33 |
| Adaptive Biotechnologies Corporation | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Janssen Biotech, Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
Products named: Fabhalta, SCEMBLIX, Vanflyta, Lenvima, clonoSEQ, LIBTAYO, Epkinly, CABOMETYX.
Industry payments across TX — which companies pay providers there.
